Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8<sup>+</sup> T cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39667270.
- Also identified by DOI 10.1016/j.ebiom.2024.105479 and PMC identifier 11697708.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Ideally, vaccination should induce protective long-lived humoral and cellular immunity. Current licensed COVID-19 mRNA vaccines focused on the spike (S) region induce neutralizing antibodies that rapidly wane. Herein, we show that a subunit vaccine (CD40.CoV2) targeting spike and nucleocapsid antigens to CD40-expressing cells elicits broad specific human (hu)Th1 CD4<sup>+</sup> and CD8<sup>+</sup> T cells in humanized mice. CD40.CoV2 vaccination selectively enriched long-lived spike- and nucleocapsid-specific CD8<sup>+</sup> progenitors with stem-cell-like memory (Tscm) properties, whereas mRNA BNT162b2 induced effector memory CD8<sup>+</sup> T cells. CD8<sup>+</sup> Tscm cells produced IFNγ and TNF upon antigenic restimulation and showed a high proliferation rate. We demonstrate that CD40 activation is specifically required for the generation of huCD8<sup>+</sup> Tscm cells. These results support the development of a CD40-vaccine platform capable of eliciting long-lasting T-cell immunity. This work was supported by Inserm, Université Paris-Est Créteil, and the Investissements d'Avenir program, Vaccine Research Institute (VRI), managed by the ANR.
Medical subject headings
- CD8-Positive T-Lymphocytes
- SARS-CoV-2
- COVID-19 Vaccines
- COVID-19
- CD40 Antigens
- Immunologic Memory
- Memory T Cells